Cassava Sciences Inc expected to post a loss of 56 cents a share - Earnings Preview

Filana Therapeutics

01/05/2023 13:25

* Cassava Sciences Inc  SAVA.OQ   SAVA.O  is expected
to show no
change in quarterly revenue when it reports  results on May 3
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Cassava Sciences
Inc is
for a loss of 56 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cassava
Sciences
Inc is $100​, above​ its last closing price of $23.22. ​​​

This summary was machine generated May 1 at 12:25 GMT.  All
figures in US dollars  unless otherwise stated